AI-designed drug for inflammatory bowel disease enters human clinical trials: 'A significant need'
Fox News
Inflammatory bowel disease (IBD) impacts 1.6 million people in the U.S. — and a new artificial intelligence drug from Insilico Medicine could help alleviate symptoms. The company's CEO shares details.
"You can think of Chemistry42 as a ChatGPT for new molecules." "As these drugs move from research labs to clinical settings, the public needs to understand the potential and the limitations." Melissa Rudy is the health editor and a member of the lifestyle team at Fox News Digital. Story tips can be sent to melissa.rudy@fox.com
This is Insilico’s fifth AI-designed drug to enter the pipeline.
More Related News
Clonazepam, popular anxiety-reducing drug, recalled nationwide for ‘possibly life-threatening’ error
The anxiety-reducing drug, Clonazepam, has been recalled after a potentially "life-threatening" label mix-up, the FDA said in the recall.